Every stock in your portfolio could theoretically go to zero. Not all at once — but if any single position would seriously hurt you if it hit zero, you own too much of it. That's the foundational principle of sound position sizing, and it shapes everything else about how a disciplined investor should think about managing a portfolio.
Position Sizing and the Discipline of Waiting
When you hold a stock with an average cost of $150 and a price target of $500, a drop to $100 does not automatically demand action. The stock is still cheap relative to your target. You still think it's going to $500. Nothing has fundamentally changed. The only moment you're forced to act is if it approaches $500 — then you trim — or if it falls so far that it becomes better than other opportunities currently available to you. Not just good. Better.
The temptation to chase a falling stock lower — doubling down, tripling down just to reduce your average cost — is a trap. There's a reason the most repeated phrase in trading is "losers average losers." You should average down rarely, and only when you have strong conviction that a genuine price dislocation has occurred. A stock drifting from $150 to $140 does not qualify. Always leave a little room to add, but don't manufacture reasons to do so.
What Kind of Edge Does Stock Picking Actually Require?
Stock investing is best understood as disciplined, high-class gambling. It is not like building a business, developing a management skill, or learning to sell — those are transferable, compounding skills. Investing is closer to poker or blackjack: there is skill involved, but variance is enormous and the house — in this case, the market — is formidable.
If you don't love it, don't do it. Most people who have built real wealth did so through their primary craft or business, not through trading. For those who are genuinely obsessed with markets, it can be a rewarding career. For everyone else, learning a technical skill — programming, sales, management — will likely generate better risk-adjusted returns on your time.
The corollary for active traders: long the best companies, short the worst ones. Strong companies with working products fall less in down markets and recover faster. Poor companies with broken fundamentals fall harder and faster. That asymmetry is the edge.
A Basic Valuation Framework: What Are You Actually Buying?
Consider a large-cap pharmaceutical company — AstraZeneca — as a worked example. The projected earnings per share trajectory looks like this:
32:10
AstraZeneca EPS projections from 2025 to 2030, showing growth from roughly $9 to $15 per share
Watch at 32:10 →
If earnings grow from roughly $9 today to $15 by 2030 — approximately 66% cumulative growth over five years — and the market applies a standard 20x earnings multiple, the stock would trade around $153 in 2030. From a current price near $90, that implies roughly an 11% annualized return.
Is 11% good? That question only has meaning when compared against alternatives:
- 10-year Treasury yield: ~4.1% (risk-free)
- AAA corporate bonds: ~5.3%
- BBB corporate bonds: ~6%
- Junk bonds: ~7%
- US equities (last 5 years): ~13% annualized
- US equities (last 10 years): ~12% annualized
- US equities (last 25 years): ~6.1% annualized
38:45
Comparative return table showing US equities across 5, 10, 15, 20, 25, 30, and 35-year periods
Watch at 38:45 →
On a 20-year basis, equity returns drop to around 9%. On a 25-year basis, 6.1%. At that level, an 11% return from a quality pharmaceutical company starts to look genuinely attractive — especially if it comes with more predictability than a broad index.
The Japan Warning: Don't Assume Markets Always Go Up
Before drawing too much comfort from US historical returns, consider Japan. The Nikkei, currently around 49,000, has delivered approximately 1% annualized over 35 years from its peak. Japan was once the world's second-largest economy. Its demographic trajectory and economic stagnation turned its equity market into a multi-decade value trap.
41:20
Nikkei index long-term return chart compared to US equity returns across equivalent time periods
Watch at 41:20 →
French equities returned 1–6% depending on the period. The lesson: US equity outperformance is not a law of nature. It reflects specific conditions — innovation, capital markets depth, rule of law, and demographic growth — that are not guaranteed to persist. Evaluating individual stocks against this backdrop matters.
Multiple Compression and the Hidden Risk
The 11% scenario assumes the market continues paying 20x earnings. But what if it contracts to 18x? That is not a dramatic shift — well within historical norms — yet the math changes drastically. If AstraZeneca's earnings grow 66% over five years but the multiple compresses from 20x to 18x, your compounded annual return turns negative 3%.
Push the scenario further: what if a new CEO underdelivers and earnings grow only 1% annually instead of 10%? Even with no earnings decline — just slow, steady growth — and an 18x multiple, the stock might deliver a 5% annualized return. That's equivalent to buying AAA corporate bonds, which carry no equity risk, no management risk, and no price volatility. At that point, why take the risk?
This is the discipline every equity investor needs to internalize. When you buy a stock, you are forgoing something else — a bond, an index fund, a different company. That opportunity cost is real. The question is never just "will this stock go up?" The question is: will it go up enough, with sufficient certainty, to justify what I'm giving up?
Framing every investment this way — as a comparison against the full spectrum of available returns, adjusted for risk — is the difference between speculation and investing with an edge.
